A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis (MS)
A Multicenter, Single Arm, Open-label, Extension, Roll-over Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants With Multiple Sclerosis
The primary purpose of this study is to evaluate the long-term safety of fenebrutinib in participants with MS who were previously enrolled in one of the eligible Roche-sponsored parent studies, including, but not limited to FENhance I (NCT04586010), FENhance II (NCT04586023), FENtrepid (NCT04544449), and FENopta (NCT05119569).
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
研究联系人备份
- 姓名:Reference Study ID Number: CN45787 https://forpatients.roche.com/ No attachments to email below.
- 电话号码:888-662-6728
- 邮箱:global-roche-genentech-trials@gene.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Previous eligibility and participation in the open-label extension (OLE) phase of an eligible Roche-sponsored parent study, where the participant is receiving fenebrutinib as an investigational medicinal product (IMP)
- Minimum of 24 weeks exposure to open-label fenebrutinib in parent study
- Ability and willingness to comply with all aspects of the protocol including completion of procedures, interviews, questionnaires, assessments for the duration of the study
Exclusion Criteria:
- Concurrent participation in any clinical trial (other than the parent study). Participants who withdrew from fenebrutinib treatment in their respective parent study should also be excluded
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
- Chronic liver disease unless considered stable for >6 months
- Acute liver disease
- Cirrhosis (Child-Pugh Class A, B, or C)
- Gilbert's syndrome
- Aspartate aminotransferase (ALT) or alanine aminotransferase (AST) > 1.5 × upper limit of normal (ULN)
- Total bilirubin greater than 1.5 × ULN
- A "yes" on any item of the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale (C-SSRS) or significant risk of a suicide, in the investigator's judgment
Note: Other protocol-defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Fenebrutinib
Participants receiving fenebrutinib in OLE of their parent study may be eligible for enrollment in this extension study. Participants will continue fenebrutinib treatment at the dosage and route of administration received at the time of rollover from the parent study. |
Fenebrutinib will be administered as per the schedule specified in the protocol.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Number of Participants With Adverse Events (AEs)
大体时间:Up to approximately 2 years
|
Up to approximately 2 years
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Change in Expanded Disability Status Scale (EDSS) Score Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in 9-hole Peg Test (9-HPT) Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Timed 25-foot Walk Test (T25FWT) Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Composite 24-week Confirmed Disability Progression (cCDP24)
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Progression (CDP24)
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of Modified cCDP24
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Time to Onset of 24-week Confirmed Disability Improvement (CDI24)
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of New or Enlarging T2 Magnetic Resonance Imaging (MRI) Lesions
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Number of T1 Hypointense MRI Lesions
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T2 Lesions
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Volume of T1 Hypointense Lesions
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Total Brain Volume
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Annualized Relapse Rate (ARR) (for Relapsing Multiple Sclerosis [RMS] Participants Only)
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Patient-reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a) Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in Multiple Sclerosis Impact Scale - 29-item (MSIS-29), Version 2 Physical Scale Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
|
Change in MSIS-29 Psychological Scale Over Time
大体时间:Up to approximately 96 weeks
|
Up to approximately 96 weeks
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-La Roche
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CN45787
- 2026-526037-26-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.